Endocrine Abstracts

Objectives: To study the relationship between hyperprolactinemia and various forms of breast cancer in women of fertile age.

Methods and materials: The study included 100 breast cancer patients, aged 25 to 43 years (mean age 34.5 ± 1.4 years). The patients were divided into 2 groups: Group I 33 patients with hyperprolactinemia, which corresponded to 33%. Group II 67 patients with breast cancer without hyperprolactinemia, which corresponded to 67%. Clinical (examination of somatic, endocrine and mammological status), hormonal, immunohistochemical, histological, and instrumental studies (ultrasound of the mammary glands, MRI of the brain with a pituitary gland, mammography) were used in the work. The studies were carried out in patients on outpatient and inpatient treatment.in 3 (9.0%) tubular carcinoma, in 2 (6%) medullary cancer, and in 1 case (3%) colloid and papillary breast cancer. In group II, in 67 patients, the distribution of the corresponding forms of breast cancer occurred in 19.4%, 16.4%, 7.5%, 10.4%, 7.5%, 6%, respectively. And also in 25 patients there were other forms of breast cancer (apocrine cancer, cystic hypersecretory carcinoma, adenoid cystic cancer. In 3 (9.0%) tubularcarcinoma, in 2 (6%) medullarycancer, andin 1 case (3%) colloidandpapillarybreastcancer. In group II, in 67 patients, the distribution of the corresponding forms of breast cancer occurred in 19.4%, 16.4%, 7.5%, 10.4%, 7.5%, 6%, respectively. And also in 25 patients there were other forms of breast cancer (apocrine cancer, cystic hypersecretory carcinoma, adenoid cystic cancer.

Conclusion: 1. The association of hyperprolactinemia due to formations of the pituitary gland is the main problem that deserves methods of their diagnosis and management.

2. Hyperprolactinemia may increase the incidence of such forms of breast cancer as ductal and lobular breast cancer in situ (63.4% vs 19.4%) and tubular carcinoma (9% vs 7.5%) in patients with breast cancer and normoprolactinemia.